Get to know our clinical trials
Trial of durvalumab and tremelimumab as first-line treatment in participants with advanced hepatocellular carcinoma
WE ARE CONDUCTING THIS STUDY TO OBTAIN INFORMATION ON THE EFFICACY AND SAFETY OF THE DRUG DURVALUMAB FOR THE TREATMENT OF ADVANCED UNRESECTABLE LIVER CANCER, WHEN GIVEN IN COMBINATION WITH TREMELIMUMAB, AND ALSO TO BETTER UNDERSTAND THE DISEASE BEING STUDIED AND THE ASSOCIATED HEALTH PROBLEMS.
Technical Summary
- PHASE IIIB, MULTICENTER, OPEN-LABEL, SINGLE-GROUP, MULTICENTER, OPEN-LABEL, PHASE IIIB STUDY OF DURVALUMAB AND TREMELIMUMAB AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. IMMUNOTHERAPY
- Code EudraCT: 2022-502012-37-00
- Protocol number: D419CR00030
- Promoter: Astra Zeneca AB
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.